myriad genetics inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. myriad is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. for more information on how myriad is making a difference, please visit the company's website: www.myriad.com.
Company profile
Ticker
MYGN
Exchange
Website
CEO
R. Bryan Riggsbee
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Myriad Genetics GmbH • Myriad Genetics Australia • Myriad International • 2 – Crescendo Bioscience, LLC ...
IRS number
870494517
MYGN stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
28 Feb 24
8-K
Results of Operations and Financial Condition
27 Feb 24
8-K
Results of Operations and Financial Condition
16 Jan 24
8-K
Departure of Directors or Certain Officers
21 Dec 23
8-K
Entry into a Material Definitive Agreement
13 Nov 23
424B5
Prospectus supplement for primary offering
13 Nov 23
8-K
Other Events
8 Nov 23
424B5
Prospectus supplement for primary offering
8 Nov 23
S-3ASR
Automatic shelf registration
8 Nov 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
Transcripts
MYGN
Earnings call transcript
2023 Q4
27 Feb 24
MYGN
Earnings call transcript
2023 Q3
6 Nov 23
MYGN
Earnings call transcript
2023 Q2
3 Aug 23
MYGN
Earnings call transcript
2023 Q1
4 May 23
MYGN
Earnings call transcript
2023 Q1
3 May 23
MYGN
Earnings call transcript
2022 Q4
28 Feb 23
MYGN
Earnings call transcript
2022 Q3
2 Nov 22
MYGN
Earnings call transcript
2022 Q2
7 Aug 22
MYGN
Earnings call transcript
2022 Q1
6 May 22
MYGN
Earnings call transcript
2021 Q4
25 Feb 22
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Jun 20 | Jun 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 85.00 mm | 85.00 mm | 85.00 mm | 85.00 mm | 85.00 mm | 85.00 mm |
Cash burn (monthly) | 9.23 mm | 2.14 mm | 20.40 mm | 23.51 mm | 7.37 mm | 5.29 mm |
Cash used (since last report) | 55.16 mm | 12.80 mm | 121.88 mm | 140.45 mm | 44.01 mm | 31.61 mm |
Cash remaining | 29.84 mm | 72.20 mm | -36.88 mm | -55.45 mm | 40.99 mm | 53.39 mm |
Runway (months of cash) | 3.2 | 33.7 | -1.8 | -2.4 | 5.6 | 10.1 |
Institutional ownership, Q3 2023
95.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 185 |
Opened positions | 17 |
Closed positions | 18 |
Increased positions | 69 |
Reduced positions | 70 |
13F shares | Current |
---|---|
Total value | 1.32 tn |
Total shares | 85.92 mm |
Total puts | 16.00 k |
Total calls | 354.50 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 13.63 mm | $218.58 bn |
Vanguard | 9.16 mm | $147.00 bn |
Camber Capital Management | 6.64 mm | $106.36 bn |
Wellington Management | 6.00 mm | $96.18 bn |
STT State Street | 4.68 mm | $75.11 bn |
Glenview Capital Management | 3.78 mm | $60.70 bn |
Millennium Management | 3.48 mm | $55.84 bn |
Earnest Partners | 3.47 mm | $55.71 bn |
D. E. Shaw & Co | 3.22 mm | $63.59 mm |
BAC Bank Of America | 3.00 mm | $48.08 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
25 Mar 24 | Natalie Munk | Common Stock | Payment of exercise | Dispose F | No | No | 21.98 | 363 | 7.98 k | 45,021 |
24 Mar 24 | Natalie Munk | Common Stock | Payment of exercise | Dispose F | No | No | 22.24 | 580 | 12.90 k | 45,384 |
24 Mar 24 | Natalie Munk | Common Stock | Payment of exercise | Dispose F | No | No | 22.24 | 401 | 8.92 k | 45,964 |
24 Mar 24 | Kevin Richard Haas | Common Stock | Payment of exercise | Dispose F | No | No | 22.24 | 1,718 | 38.21 k | 132,097 |
24 Mar 24 | Kevin Richard Haas | Common Stock | Payment of exercise | Dispose F | No | No | 22.24 | 1,172 | 26.07 k | 133,815 |
22 Mar 24 | Pamela Wong | Common Stock | Payment of exercise | Dispose F | No | No | 22.24 | 1,441 | 32.05 k | 65,002 |
22 Mar 24 | Natalie Munk | Common Stock | Payment of exercise | Dispose F | No | No | 22.24 | 363 | 8.07 k | 46,365 |
22 Mar 24 | Margaret Ancona | Common Stock | Payment of exercise | Dispose F | No | No | 22.24 | 730 | 16.24 k | 90,904 |
22 Mar 24 | Kevin Richard Haas | Common Stock | Payment of exercise | Dispose F | No | No | 22.24 | 1,685 | 37.47 k | 134,987 |
News
Myriad Genetics Says US Patent And Trademark Office Has Granted Patent That Covers Use Of Push-Button Blood Collection Devices For PCR-Based Fetal Sex Determination
20 Mar 24
Myriad Genetics: Q4 Earnings Insights
27 Feb 24
Myriad Genetics Q4 2023 Adj EPS $0.04 Beats $0.01 Estimate, Sales $196.60M Beat $194.78M Estimate
27 Feb 24
Myriad Genetics And National Cancer Center Hospital East In Japan Collaborate On Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3
27 Feb 24
Earnings Scheduled For February 27, 2024
27 Feb 24
Press releases
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
21 Mar 24
Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device
20 Mar 24
Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3
27 Feb 24
Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
1 Feb 24
Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology
30 Jan 24